Last reviewed 2026-04-23 · How we verify

Metformin XR plus liraglutide

Metformin XR reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and reduces glucagon in a glucose-dependent manner via GLP-1 receptor activation.

Metformin XR reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and reduces glucagon in a glucose-dependent manner via GLP-1 receptor activation. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, primarily through AMPK activation. Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal distress
• Headache
• Hypoglycemia

Key clinical trials

• Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility (PHASE3)
• Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) (PHASE3)
• A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) (PHASE2)
• Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.